Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on June 22, 2009

Hypertension. 2009
Published online before print June 22, 2009, doi: 10.1161/HYPERTENSIONAHA.108.121731
A more recent version of this article appeared on August 1, 2009
This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
54/2/294    most recent
HYPERTENSIONAHA.108.121731v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Huynh, N. N.
Right arrow Articles by Chin-Dusting, J. P.F.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Huynh, N. N.
Right arrow Articles by Chin-Dusting, J. P.F.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*(L)-ARGININE
*NITRIC OXIDE
*UREA
Medline Plus Health Information
*High Blood Pressure
Related Collections
Right arrow Other hypertension
Right arrow Endothelium/vascular type/nitric oxide

Submitted on August 20, 2008
Revised on September 13, 2008

Arginase II Knockout Mouse Displays a Hypertensive Phenotype Despite a Decreased Vasoconstrictory Profile

Ngan N. Huynh; Karen L. Andrews; Geoffrey A. Head; Sacha M.L. Khong; Dmitry N. Mayorov; Andrew J. Murphy; Gavin Lambert; Helen Kiriazis; Qi Xu; Xiao-Jun Du; and Jaye P.F. Chin-Dusting*

From the Baker IDI Heart and Diabetes Institute, Melbourne, Australia.

* To whom correspondence should be addressed. E-mail: jaye.chin-dusting{at}bakeridi.edu.au.

Abstract—Arginase upregulation is associated with aging and cardiovascular diseases. In this study we report on the cardiovascular phenotype of the arginase II knockout (KO) mouse. We demonstrate that vascular sensitivity and reactivity altered over time in these animals such that no influence on responses to vasoconstrictor activity was observed in 7-week-old KO mice, but dampened responses to norepinephrine and phenylephrine were observed by 10 and 15 weeks with Rho kinase influencing these effects in the 15-week-old animals. Despite these dampened vasoconstrictory responses, KO mice demonstrated increased mean arterial pressure from 8 weeks old. This hypertensive phenotype was associated with an increase in left ventricular weight, left ventricular systolic pressure, and diminished diastolic function. KO mice also show enhanced plasma norepinephrine turnover, suggesting an increased sympathetic outflow. In conclusion, our data suggest that global loss of arginase II activity results in hypertension. We suggest that this strain of mouse warrants further investigation as a potentially novel model of hypertension.


Key words: arginase • NO • hypertension • vasculature • L-arginine